MARKET

ACHV

ACHV

Achieve Life Sciences Inc
NASDAQ
4.970
+0.270
+5.74%
After Hours: 4.902 -0.068 -1.38% 19:58 12/31 EST
OPEN
4.700
PREV CLOSE
4.700
HIGH
4.980
LOW
4.690
VOLUME
823.32K
TURNOVER
--
52 WEEK HIGH
5.78
52 WEEK LOW
1.840
MARKET CAP
264.57M
P/E (TTM)
-3.6077
1D
5D
1M
3M
1Y
5Y
1D
New Report Calls Achieve Life's Cytisinicline Best Therapy To Quit Smoking
Benzinga · 12/30/2025 18:23
Achieve Life Sciences jumps on Hunterbrook Capital endorsement
Seeking Alpha · 12/30/2025 17:18
Watching Achieve Life Sciences; Shares Trading Higher, Hunterbrook Media Issues Report On Co, States Hunterbrook Capital Is Long
Benzinga · 12/30/2025 16:17
Achieve Life near FDA approval of smoking addiction treatment, Hunterbrook says
TipRanks · 12/30/2025 16:10
Weekly Report: what happened at ACHV last week (1222-1226)?
Weekly Report · 12/29/2025 09:15
Weekly Report: what happened at ACHV last week (1215-1219)?
Weekly Report · 12/22/2025 09:15
ACHIEVE CLOSES ITS FIRST DEBT SETTLEMENT FEE SECURITIZATION
Reuters · 12/18/2025 18:43
Achieve Life Sciences to Host Meetings During J.P. Morgan Healthcare Conference
Reuters · 12/17/2025 21:12
More
About ACHV
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.

Webull offers Achieve Life Sciences Inc stock information, including NASDAQ: ACHV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACHV stock methods without spending real money on the virtual paper trading platform.